Kezdőlap › Tüdőrák › Georgia › Atlanta
Tüdőrák klinikai vizsgálatok: Atlanta, GA
29 Tüdőrák vizsgálat keres résztvevőket Atlanta és környéke (kb. 30 mérföldes körzetben) helyszínein. Nyissa meg a vizsgálatot, hogy lássa, ki csatlakozhat, és hogyan léphet kapcsolatba a csapattal.
Hivatalos vizsgálati szöveg (angol)
Vizsgálatra keres résztvevőket? Emelje ki az oldal tetején — $99 / 30 nap →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Toborzás folyamatban3. fázis
- Northside Hospital, Atlanta
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Toborzás folyamatban3. fázis
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Toborzás folyamatbanMegfigyeléses tanulmányEgészséges önkéntesek is jelentkezhetnek
- Atlanta VA Medical Center, Decatur · 6 mérföldre
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Toborzás folyamatban3. fázis
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
- és további 1
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Toborzás folyamatban3. fázis
- Winship Cancer Institute of Emory University, Atlanta
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Toborzás folyamatban3. fázis
- Piedmont Healthcare, Inc, Atlanta
- Winship Cancer Institute, Atlanta
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Toborzás folyamatban3. fázis
- Piedmont Atlanta Hospital ( Site 4000), Atlanta
- Emory University School of Medicine-Phase I ( Site 0056), Atlanta
- Northside Hospital ( Site 0055), Atlanta
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Toborzás folyamatban2/3. fázis
- Piedmont Healthcare, Atlanta
Empowering Patients' Lung Cancer Screening Uptake (Empower LCS/Call+)
Toborzás folyamatban
- Emory Clinic at Old Fourth Ward, Atlanta
- Emory Clinic at Midtown, Atlanta
- Emory at Peachtree Hills - Primary Care, Atlanta
- és további 19
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Toborzás folyamatban1/2. fázis
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Toborzás folyamatban3. fázis
- Emory University School of Medicine- Grady Campus, Atlanta
- Winship Cancer Institute, Emory University, Atlanta
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Toborzás folyamatban3. fázis
- Piedmont Cancer Institute, PC, Atlanta
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Toborzás folyamatban1. fázis
- Emory University, Atlanta
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Toborzás folyamatban1/2. fázis
- Avenzo Therapeutics Recruiting Site, Atlanta
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Toborzás folyamatban3. fázis
- Northside Hospital Atlanta, Atlanta
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Toborzás folyamatban1. fázis
- Emory University - Winship Cancer Institute, Atlanta
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Toborzás folyamatban3. fázis
- Grady Health System, Atlanta
- Emory Proton Therapy Center, Atlanta
- Emory University Hospital Midtown, Atlanta
- és további 3
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Toborzás folyamatban1. fázis
- Xencor Investigative Site, Atlanta
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Toborzás folyamatban1/2. fázis
- Winship Cancer Institute - Emory University, Atlanta
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Toborzás folyamatban2. fázis
- Northside Hospital, Atlanta
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Toborzás folyamatban1/2. fázis
- Piedmont Healthcare, Atlanta
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Toborzás folyamatban2/3. fázis
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- és további 3
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
Toborzás folyamatban2. fázis
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
Toborzás folyamatban1. fázis
- Emory University Hospital/Winship Cancer Institute, Atlanta
Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer
Toborzás folyamatbanKorai 1. fázis
- Emory University/Winship Cancer Institute, Atlanta
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
Toborzás folyamatban2. fázis
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
Toborzás folyamatbanMegfigyeléses tanulmány
- Northside Hospital, Atlanta
Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
Toborzás folyamatban1. fázis
- Emory University Hospital Midtown, Atlanta
- Emory University, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Toborzás folyamatbanMegfigyeléses tanulmány
- Massive Bio SYNERGY-AI site, Atlanta
Tüdőrák vizsgálatok más városokban
- Houston, TX78 tanulmány
- Boston, MA62 tanulmány
- New York City, NY60 tanulmány
- Los Angeles, CA45 tanulmány
- Arlington, VA41 tanulmány
- Washington, DC41 tanulmány
- Chicago, IL41 tanulmány
- Baltimore, MD40 tanulmány
- Nashville, TN40 tanulmány
- St. Louis, MO39 tanulmány
- Columbus, OH37 tanulmány
- Philadelphia, PA36 tanulmány
Egyéb vizsgálatok: Atlanta
- Rák (minden típus)49 tanulmány
- Nem kis sejtes tüdőrák47 tanulmány
- Multiplex mielóma42 tanulmány
- Mellrák41 tanulmány
- Prosztatarák33 tanulmány
- Akut mieloid leukémia31 tanulmány
- Petefészekrák29 tanulmány
- Kolorektális rák29 tanulmány
- Áttétes rák28 tanulmány
- Súlyos depressziós zavar25 tanulmány
- Szívelégtelenség25 tanulmány
- Fej- és nyaki laphámrák24 tanulmány
Forrás: ClinicalTrials.gov, adatok lekérve: 2026. okt. 6.. Minden vizsgálat saját alkalmassági feltételeket határoz meg; a döntést a vizsgálati csapat hozza meg.